Association of Probiotics With Neurostimulation of Dermatome T6: Effect on Weight Loss in Obese Patients
NCT ID: NCT03872245
Last Updated: 2019-03-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
20 participants
INTERVENTIONAL
2019-03-11
2019-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Group 1:Patients undergoing PENS T6, who also received Probiotics, during 10 weeks.
* Group 2: Patients undergoing PENS T6 during 10 weeks. They will not received Probiotics
Weight loss after 10 weeks of treatmente will be assessed.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Percutaneous Electroneurostimulation of Dermatome T6 for Appetite Reduction and Weight Loss in Morbidly Obese Patients
NCT01792947
Weight Loss and Appetite Reduction After Percutaneous Electrical Stimulation Dermatome T6
NCT02810925
Effect of a Probiotic on Visceral Fat Accumulation
NCT02921217
Dermatome Electrical Stimulation on Individuals With Overweight and Class I Obesity
NCT03261531
Evaluate the Efficacy and Safety of LMT1-48 on Reducing Body Fat in Overweight Subject
NCT03759743
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Group 1:Patients undergoing percutaneous electrical stimulation of dermatome T6 (PENS T6), who also received Probiotics (Adomelle 1 caps/12h), during 10 weeks.
* Group 2: Patients undergoing PENS T6 during 10 weeks. They will not received Probiotics
Weight loss after 10 weeks of treatmente will be assessed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PENS T6 + Probiotics
The patients will receive Probiotics (Adomelle 1caps/12h) associated to PENS T6 during 10 weeks.
Probiotics
The patients will receive Adomelle 1caps/12h during 10 weeks
PENS T6
The patients will undergo percutaneous electrical neurostimulation of dermatome T6 weekle, during 10 weeks
PENS T6
The patients will undergo PENS T6 during 10 weeks.
PENS T6
The patients will undergo percutaneous electrical neurostimulation of dermatome T6 weekle, during 10 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Probiotics
The patients will receive Adomelle 1caps/12h during 10 weeks
PENS T6
The patients will undergo percutaneous electrical neurostimulation of dermatome T6 weekle, during 10 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Pregnant women
* History of allergy to Probiotics
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospital General Universitario Elche
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jaime Ruiz-Tovar, MD, PhD
Department of Surgery
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Carolina Llavero
Role: STUDY_DIRECTOR
Hospital Rey Juan Carlos
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Garcilaso 19-3
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.